The ongoing conflict in the Middle East is disrupting critical air cargo routes used to transport pharmaceutical products, raising concerns about the timely supply of cancer medicines and other temperature-sensitive treatments to the Gulf region.

Industry executives say the crisis has affected key aviation hubs and shipping corridors that pharmaceutical companies rely on for delivering medicines requiring strict cold-chain logistics. The disruptions have forced companies to reroute flights and explore alternative transport routes to maintain supplies of essential treatments.

The conflict, which escalated following military strikes involving the United States, Israel and Iran, has led to airspace closures and disruptions in major transit hubs across the region. As a result, pharmaceutical shipments that usually move through airports in cities such as Dubai, Abu Dhabi and Doha are being diverted to alternative hubs including Jeddah, Riyadh, Istanbul and Oman.

These disruptions pose a particular challenge for medicines such as oncology treatments that require constant refrigeration and rapid transportation. Unlike many other goods, these medicines cannot withstand long transit delays or exposure to temperature fluctuations.

Pharmaceutical companies and logistics providers are currently managing the situation by rerouting shipments and, in some cases, transporting medicines by road from alternative airports into Gulf countries. However, such adjustments increase transportation costs, extend delivery times and add operational complexity to already sensitive supply chains.

Experts warn that if the conflict continues for several weeks, hospitals in the region could begin to experience shortages of certain medicines, particularly those with shorter shelf lives. While significant shortages have not yet been widely reported, the risk is expected to rise if logistical disruptions persist.

The broader crisis has also affected maritime transport routes. Shipping disruptions around strategic corridors such as the Strait of Hormuz have further complicated the movement of goods across the region, leaving companies increasingly dependent on alternative logistics networks.

For the pharmaceutical industry, the situation highlights the vulnerability of global medicine supply chains to geopolitical tensions. Many life-saving medicines depend on precise and uninterrupted logistics systems that span multiple countries and transport hubs.

Industry leaders say companies are closely monitoring the situation and working with logistics partners to maintain supply continuity. However, prolonged instability in the region could place additional strain on pharmaceutical distribution networks and increase the risk of treatment delays for patients.